Reviewing REGENXBIO Inc. (RGNX)’s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)’s results

REGENXBIO Inc. (NASDAQ:RGNX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
REGENXBIO Inc. 48 25.08 N/A -1.04 0.00
TRACON Pharmaceuticals Inc. 1 0.00 N/A -1.13 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of REGENXBIO Inc. and TRACON Pharmaceuticals Inc.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both companies.

Net Margins Return on Equity Return on Assets
REGENXBIO Inc. 0.00% -8.1% -7.6%
TRACON Pharmaceuticals Inc. 0.00% -132.9% -75.9%

Risk and Volatility

REGENXBIO Inc.’s 0.67 beta indicates that its volatility is 33.00% less volatile than that of Standard and Poor’s 500. From a competition point of view, TRACON Pharmaceuticals Inc. has a 2.39 beta which is 139.00% more volatile compared to Standard and Poor’s 500.

Liquidity

REGENXBIO Inc.’s Current Ratio is 14.2 while its Quick Ratio is 14.2. On the competitive side is, TRACON Pharmaceuticals Inc. which has a 2.4 Current Ratio and a 2.4 Quick Ratio. REGENXBIO Inc. is better positioned to pay off short and long-term obligations compared to TRACON Pharmaceuticals Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for REGENXBIO Inc. and TRACON Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
REGENXBIO Inc. 0 1 0 2.00
TRACON Pharmaceuticals Inc. 0 0 1 3.00

REGENXBIO Inc. has a -1.02% downside potential and a consensus target price of $37. Competitively TRACON Pharmaceuticals Inc. has a consensus target price of $2, with potential upside of 295.65%. Based on the analysts belief we can conclude, TRACON Pharmaceuticals Inc. is looking more favorable than REGENXBIO Inc.

Insider and Institutional Ownership

REGENXBIO Inc. and TRACON Pharmaceuticals Inc. has shares held by institutional investors as follows: 89.1% and 65.7%. REGENXBIO Inc.’s share held by insiders are 1.4%. Comparatively, 8.89% are TRACON Pharmaceuticals Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
REGENXBIO Inc. -12.25% -12.72% -8.62% 3.42% -33.32% 5.86%
TRACON Pharmaceuticals Inc. -16.98% -34.33% -30.49% -45.67% -82.4% -30.16%

For the past year REGENXBIO Inc. had bullish trend while TRACON Pharmaceuticals Inc. had bearish trend.

Summary

REGENXBIO Inc. beats TRACON Pharmaceuticals Inc. on 7 of the 9 factors.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV vectors to various other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.